BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2355780)

  • 1. [Chronic myeloproliferative syndromes and tuberculosis: apropos of 3 cases].
    Peró Silva A; García Saavedra V; Llorente Cabrera A
    Med Clin (Barc); 1990 Apr; 94(15):582-4. PubMed ID: 2355780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tuberculosis in chronic myeloproliferative syndromes: its incidence and principle characteristics in a series of 562 patients].
    Tassies D; Cervantes F; Nicolás JM; Feliu E; Soriano E; Rozman C
    Med Clin (Barc); 1991 Mar; 96(9):321-3. PubMed ID: 2046440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycobacterium tuberculosis infection in allogeneic bone marrow transplantation patients.
    Aljurf M; Gyger M; Alrajhi A; Sahovic E; Chaudhri N; Musa M; Ayoub O; Seth P; Aslam M; Al-Fiar F
    Bone Marrow Transplant; 1999 Sep; 24(5):551-4. PubMed ID: 10482941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The chronic myeloproliferative disorders: an historical perspective.
    Steensma DP
    Curr Hematol Rep; 2003 May; 2(3):221-30. PubMed ID: 12901343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megakaryoblastic termination of myeloproliferative disorders.
    Amin MB; Maeda K; Carey JL; Babu RV; Raman BK
    Henry Ford Hosp Med J; 1992; 40(1-2):122-6. PubMed ID: 1428963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders?
    Roumier C; Daudignon A; Soenen V; Dupriez B; Wetterwald M; Lai JL; Cosson A; Fenaux P; Preudhomme C
    Haematologica; 1999 Dec; 84(12):1075-80. PubMed ID: 10586207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An unusual chronic myeloproliferation].
    Kolesková E; Háber J; Klener P
    Vnitr Lek; 1989 May; 35(5):489-92. PubMed ID: 2763484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
    Cortes J; Kantarjian H
    Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pneumoconiosis and mycobacterial infection].
    Kekkaku; 2003 Nov; 78(11):711-5. PubMed ID: 14672049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
    Nakata Y
    Hiroshima J Med Sci; 1993 Jun; 42(2):67-71. PubMed ID: 8253600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Platelet defects in chronic myeloproliferative disorders].
    Raszeja-Specht A; Skibowska A; Kabata J; Hellmann A
    Acta Haematol Pol; 1994; 25(3):253-60. PubMed ID: 7992598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases.
    Guilpain P; Montani D; Damaj G; Achouh L; Lefrère F; Le Pavec J; Marfaing-Koka A; Dartevelle P; Simonneau G; Humbert M; Hermine O
    Respiration; 2008; 76(3):295-302. PubMed ID: 18160817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloproliferative neoplasms cause glomerulopathy.
    Said SM; Leung N; Sethi S; Cornell LD; Fidler ME; Grande JP; Herrmann S; Tefferi A; D'Agati VD; Nasr SH
    Kidney Int; 2011 Oct; 80(7):753-9. PubMed ID: 21654720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A myeloproliferative disorder may hide another one.
    Laibe S; Tadrist Z; Arnoulet C; Sainty D; Mozziconacci MJ
    Leuk Res; 2009 Aug; 33(8):1133-6. PubMed ID: 19250672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.